A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Plain-language summary

This study evaluates the drug ASKG915 in patients with advanced solid tumors that are refractory to or intolerant of all standard therapy; treatments such as Paclitaxel, Bevacizumab, Fruquintinib, and Docetaxel are also used for comparison. It enrolls patients with an ECOG performance status of 2 or better. It is in Phase 1/Phase 2 and is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Recruiting

Sponsor

AskGene Pharma, Inc.

Intervention

ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel

Start date

8/2/2023

Estimated completion

6/30/2028

Countries

United States, China

Related genes

Locations

• New York, United States
• Pittsburgh, United States
• Beijing, China
• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
2. ECOG performance status of ≤ 2.
3. Life expectancy of ≥ 3 months.
4. The results of the laboratory tests must meet all criteria.

Exclusion Criteria:

1. Patients have received antitumor therapy during the first 4 weeks before study drug use.
2. Received a live attenuated vaccine within 4 weeks prior to C1D1.
3. Known cerebral parenchymal metastasis or meningeal metastasis.
4. History of serious cardiovascular or cerebrovascular diseases.
5. Active or recurrent autoimmune diseases.
6. History of ascites or pleural effusion requiring drainage.
7. Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.